Zusammenfassung

In den letzten Jahren wurden in der Prophylaxe und Therapie von chemo- und strahlentherapieinduzierter Übelkeit und Erbrechen durch die Entwicklung der 5-HT3-Rezeptorantagonisten große Fortschritte gemacht. Erbrechen nach Chemotherapie ist nicht länger unvermeidbar, sondern wird zunehmend zur Ausnahme. Die Verfügbarkeit mehrerer Serotoninantagonisten und der hohe Preis machen einen differenzierten Einsatz dieser Medikamente unerläßlich. Im Folgenden werden die verschiedenen Formen der Emesis, die emetogene Potenz verschiedener Zytostatika und Vorschläge zur antiemetischen Prophylaxe und Therapie dargestellt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur zu 3

  1. Aapro MS (1988) Corticosteroids as Antiemetics. Recent Results Cancer Res 108: 102–111PubMedGoogle Scholar
  2. Barrenetxea G, Schneider J, Centeno MM, Romero H, Rica M de la, Rodriguez-Escudero FJ (1996) Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens. Cancer Chemother Pharmacol 38: 471–475PubMedCrossRefGoogle Scholar
  3. Casper J, Aapro MS, Schmoll H-J (1996) Richtlinien zur antiemetischen Therapie. In: Schmoll A et al. (Hrsg) Kompendium der internistischen Onkologie, 2. Aufl. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  4. Dominguez-Ortega L, Cubedo-Cervera R, Cortes-Funes H., Diaz-Gallego E. (1996) Sleep protects against chemotherapy induced emesis. Cancer 77: 1566–1570PubMedCrossRefGoogle Scholar
  5. Gralla RJ, Popovic W, Strupp J et al. (1997) Can an oral antiemetic regimen be as effective as intravenous treatment against cisplatin: results of a 1054 patient randomized study of oral granisetron vs. IV ondansetron. Proc Am Soc Clin Oncol 16: 52 aGoogle Scholar
  6. Gyermek L (1995) 5-HT3 receptors: pharmacologic and therapeutic aspects. J Clin Pharmacol 35: 845–855PubMedGoogle Scholar
  7. Hesketh PJ, Kris MG, Grunberg SM et al. (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15: 103–109PubMedGoogle Scholar
  8. Hursti TJ, Avall-Lundqvist E, Borjeson S et al. (1996) Impact of tumour burden on chemotherapy-induced nausea and vomiting. Br J Cancer 74: 1114–1119PubMedCrossRefGoogle Scholar
  9. Jones AL, Hill AS, Sovkop M et al. (1991) Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338: 483–487PubMedCrossRefGoogle Scholar
  10. Laszlo J, Clark RA, Hanson DC, Tyson L, Crumpler L, Cralla R (1985) Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic, and anxiolytic effects. J Clin Oncol 3: 864–869PubMedGoogle Scholar
  11. Lichter I (1996) Nausea and vomiting in patients with cancer. Hematol Oncol Clin North Am 10: 207–220PubMedCrossRefGoogle Scholar
  12. Lipp H-P (1994) Metabolismus und Toxizität von Zytostatika. Krankenhauspharmazie, 15/5: 269–278Google Scholar
  13. Lipp H-P (1995) Prevention and management of anticancer drug toxicity — the significance of clinical pharmacokinetics. Unversitätsverlag, JenaGoogle Scholar
  14. Mantovani G, Maccio A et al. (1996) Comparison of granisetron, odansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: A randomized controlled trial. Cancer 77: 941–948PubMedCrossRefGoogle Scholar
  15. Martoni A, Angelelli B, Guaraldi M, Strocchi E, Pannuti F (1996) An open randomised cross-over study on granisetron vs. ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Eur J Cancer 32 A: 82–85CrossRefGoogle Scholar
  16. Morrow GR, Hickok JT, Rosenthal SN (1995) Progress in reducing nausea and emesis. Comparisons of ondansetron (zofran), granisetron (kytril), and tropisetron (navoban). Cancer 76: 343–357PubMedCrossRefGoogle Scholar
  17. Morrow GR, Rosenthal SN (1996) Models, mechanisms and management of anticipatory nausea and emesis. Oncology 53 (Suppl 1): 4–7PubMedCrossRefGoogle Scholar
  18. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15: 116–123PubMedGoogle Scholar
  19. Perez EA (1995) Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryp-tamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 13: 1036–1043PubMedGoogle Scholar
  20. Verweij J, Wit R de, Mulder PH de (1996) Optimal control of acute cisplatin-induced emesis. Oncology 53 (Suppl 1): 56–64PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • M. Sökler

There are no affiliations available

Personalised recommendations